Moberg Pharma AB (OMX: MOB) announces that Terclara® is the market leader in Sweden for the month of April, the first full month the product is available with promotion. The aim for the launch in Sweden was to achieve a market-leading position, which has already been accomplished.
STOCKHOLM, May 6th, 2024, Moberg Pharma AB (OMX:MOB) hereby announces that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries.
The launch to pharmacies was initiated in February. A majority of ~1,400 Swedish pharmacies now have MOB-015 available on the shelf under the brand name Terclara® and interest is exceeding the chains’ forecasts. The pharmacy chains are increasing their orders after consumer marketing began around the end of March due to the fact that the product occasionally has sold out at several of the pharmacy chains. However, there is a well-stocked wholesale warehouse.
STOCKHOLM, Oct. 6, 2023 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S.. Topline results are expected in January 2025.
Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian...
STOCKHOLM, Nov. 8, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has entered into a collaboration with Allderma AB for the launch of MOB-015 (for nail fungus) in Sweden, Norway and Denmark. Allderma is managed by the commercial leaders which were responsible for the successful Nordic launch of Nalox®, Moberg Pharma's first-generation nail fungus product.
STOCKHOLM, Sept. 22, 2021 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announces that it has received approval of the pediatric plan for MOB-015 from EMA's paediatric committee (PDCO). This approval enables the company to pursue a full marketing authorization application providing up to ten years of exclusivity in Europe following approval. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.
STOCKHOLM, Nov. 6, 2020 /PRNewswire/ -- The Board of Directors of Moberg Pharma AB (OMX: MOB) today announces its intention to distribute the operations of BupiZenge® (BUPI) to the shareholders of Moberg Pharma by distributing 90 percent of the shares in a subsidiary (name to be changed to OncoZenge AB) through a so-called Lex ASEA distribution, and convenes an extraordinary general meeting to resolve accordingly. The business consists of developing the BUPI project under the brand name BupiZenge® for treatment of oral mucositis. Moberg Pharma estimates the capital requirement to take BupiZenge® through phase 3 at SEK 60 million. Moberg Pharma is therefore evaluating the opportunity to distribute OncoZenge according to Lex Asea and list its shares on Nasdaq First North Growth Market. Moberg Pharma has hired Erik Penser Bank to evaluate opportunities for financing OncoZenge as a separate company.